Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Orphan Disclosures Could Increase Under Tweaks Proposed By FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency considering whether to tell public if sponsors have submitted annual product development reports as part of proposed rule clarifying portions of 1992 Orphan Drug Regulations.

You may also be interested in...

Orphan Designation Removals To Be Revealed By FDA

List will include whether a designation was lost, but not why, FDA says in final rule clarifying and updated 1992 orphan drug regulations.

FDA’s Rulemaking To-Do List Includes Clarifying Citizen Petitions And Orphan Drug Designations

FDA pending actions include proposed rules on the handling of citizen petitions, eligibility for orphan drug designation and post-market safety reporting for combination products.

Regulatory Flexibility Staring Contest: Will Industry Or FDA Blink First?

FDA may be able to talk in theoretical terms about the flexibility it is afforded for orphan products approvals, but others seem to want more tangible evidence. For its part, the agency wants more than general complaints about its regulations; it wants an open discussion of specific roadblocks.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts